Results 1 to 10 of about 110,603 (154)
Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells [PDF]
Frontiers in PharmacologyMultiple myeloma is an incurable cancer that originates from antibody-producing plasma cells. It is characterized by an intrinsic ability to produce large amounts of immunoglobulin-like proteins.
Irena Misiewicz-Krzeminska +1 more
exaly +4 more sources
Site-Specific Proteasome Inhibitors [PDF]
Biomolecules, 2021 Proteasome is a multi-subunit protein degradation machine, which plays a key role in the maintenance of protein homeostasis and, through degradation of regulatory proteins, in the regulation of numerous cell functions. Proteasome inhibitors are essential
Alexei F. Kisselev
doaj +3 more sources
Early recovery of proteasome activity in cells pulse-treated with proteasome inhibitors is independent of DDI2 [PDF]
eLifeRapid recovery of proteasome activity may contribute to intrinsic and acquired resistance to FDA-approved proteasome inhibitors. Previous studies have demonstrated that the expression of proteasome genes in cells treated with sub-lethal concentrations of
Ibtisam Ibtisam, Alexei F Kisselev
doaj +2 more sources
Proteasome inhibitors in cancer therapy [PDF]
Nature Reviews Clinical Oncology, 2017 The ubiquitin proteasome pathway was discovered in the 1980s to be a central component of the cellular protein-degradation machinery with essential functions in homeostasis, which include preventing the accumulation of misfolded or deleterious proteins.
Elisabet E Manasanch, Robert Z Orlowski
exaly +3 more sources
FoxM1 Is a General Target for Proteasome Inhibitors [PDF]
PLoS ONE, 2009 Proteasome inhibitors are currently in the clinic or in clinical trials, but the mechanism of their anticancer activity is not completely understood. The oncogenic transcription factor FoxM1 is one of the most overexpressed genes in human tumors, while ...
Andrei Gartel, Marianna HalaĊĦi
exaly +2 more sources
Protocol for analysis of intracellular conversion of artezomib molecules into new proteasome inhibitors in Plasmodium falciparum parasites [PDF]
STAR ProtocolsSummary: Artezomibs (ATZs), dual-pharmacophore molecules comprising of artemisinin and a parasite proteasome inhibitor, hijack parasite ubiquitin proteasome system to transform into new proteasome inhibitors following the activation of artemisinin by ...
Wenhu Zhan +3 more
doaj +2 more sources
The Role of Proteasome Inhibitors in Treating Acute Lymphoblastic Leukaemia
Frontiers in Oncology, 2021 Acute lymphoblastic leukaemia (ALL) is an aggressive haematolymphoid malignancy. The prognosis of ALL is excellent in paediatric population, however the outcome of relapse/refractory disease is dismal.
Chun-fung Sin, Pui-hei Marcus Man
doaj +1 more source
Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease
Molecules, 2020 The proteasome is the central component of the main cellular protein degradation pathway. During the past four decades, the critical function of the proteasome in numerous physiological processes has been revealed, and proteasome activity has been linked
David J. Sherman, Jing Li
doaj +1 more source
Biomolecules, 2020 Currently, proteasome inhibitors bortezomib, carfilzomib, and ixazomib are successfully used in clinics to treat multiple myeloma. However, these agents show limited efficacy against solid tumors. Identification of drugs that can potentiate the action of
Janakiram R. Vangala +2 more
doaj +1 more source
Biochemical Pharmacology, 2015 Proteasome inhibitors have a 20 year history in cancer therapy. The first proteasome inhibitor, bortezomib (Velcade, PS-341), a break-through multiple myeloma treatment, moved rapidly through development from bench in 1994 to first approval in 2003. Bortezomib is a reversible boronic acid inhibitor of the chymotrypsin-like activity of the proteasome ...
Teicher, Beverly A. +1 more
openaire +4 more sources